ACC.14
TCT@ACC-i2 | innovation in intervention

A1815
JACC April 1, 2014
Volume 63, Issue 12

TCT@ACC-i2: The Interventional Learning Pathway

ASSOCIATIONS BETWEEN DUAL ANTIPLATELET THERAPY CESSATION AND MACE DUE TO STOPPING ONE OR BOTH DRUGS: INSIGHTS FROM THE PARIS REGISTRY

Poster Contributions
Hall C
Sunday, March 30, 2014, 9:45 a.m.-10:30 a.m.

Session Title: PCI Pharmacology
Abstract Category: 36. TCT@ACC-i2: ACS/AMI/Hemodynamics and Pharmacology
Presentation Number: 2105-291

Authors: *Usman Baber, Mikkel Schoos, Samantha Sartori, Philippe Steg, Cono Ariti, Giora Weisz, Bernhard Witzenbichler, Timothy Henry, Annapoorna Kini, Thomas Stuckey, David Cohen, Peter B. Berger, Ioannis Iakovou, George Dangas, Ron Waksman, Mitchell Krucoff, James Hermiller, Fayaz Shawl, C Michael Gibson, Alaide Chieffo, Maria Alu, David Moliterno, Antonio Colombo, Stuart Pocock, Roxana Mehran, Mount Sinai Medical Center, New York, NY, USA*

Background: Dual anti-platelet therapy (DAPT) is the current standard treatment after percutaneous coronary intervention (PCI). We aimed to investigate the associations between DAPT cessation and MACE due to stopping 1 or both drugs, in an all-comer PCI population undergoing contemporary stenting.

Methods: The PARIS (patterns of non-adherence to anti-platelet regiments in stented patients) registry was a prospective observational multicenter study of patients undergoing contemporary PCI. Pre-specified categories for DAPT cessation included physician-recommended discontinuation, brief interruption for surgery or disruption (due to non-compliance or bleeding). We examined the effect of DAPT cessation on major adverse events (MACE - cardiac death, def./prob. stent thrombosis, myocardial infarction and target lesion revascularization).

Results: In 5018 patients, overall DAPT cessation was 57.3% and 558 (11.5%) MACE had occurred at 2 years follow-up. All presented hazard ratios (table) are adjusted for age, gender, region, stent type, number of stents and ACS diagnosis. DAPT cessation due to stopping 1 or both drugs was entered as a time-updated covariate within each mode of DAPT cessation. The results were unchanged after adjusting or stratifying by original recommended DAPT duration at discharge.

Conclusion: The present analysis suggests that recommended DAPT discontinuation is safe for both drugs, whereas disruption of both drugs compared to one carries substantial additional risk.

Variable	Hazard ratio	95% CI	MACE Events (n)	P-value
On DAPT	1.000		413	
Discontinuation - 1 drugs	0.627	(0.456, 0.863)	50	0.004
Discontinuation - 2 drugs	1.153	(0.286, 4.651)	2	0.841
Interruption - 1 drugs	1.419	(0.807, 2.494)	13	0.224
Interruption - 2 drugs	1.449	(0.826, 2.539)	13	0.196
Disruption - 1 drugs	1.315	(0.955, 1.812)	45	0.094
Disruption - 2 drugs	2.109	(1.360, 3.269)	22	<0.001